Atrial Fibrillation Network
17
1
2
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
17.6%
3 terminated/withdrawn out of 17 trials
76.9%
-9.6% vs industry average
35%
6 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
From the Emergency Department Directly to Ablation of Atrial Fibrillation Study
Role: collaborator
Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair
Role: lead
Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)
Role: lead
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
Role: collaborator
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
Role: lead
Clinical Cohorts for Validation of New Digital Biomarkers
Role: lead
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
Role: lead
The Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study (Smart in OAC - AFNET 9)
Role: lead
Prospective Registration and Assessment of Serious Adverse Events Within the AFNET
Role: lead
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial
Role: lead
Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF
Role: collaborator
Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
Role: lead
Flecainide-Short Long Study (Flec-SL)
Role: lead
Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation
Role: lead
Recurrence of Atrial Fibrillation in Patients With Dual-chamber Pacemakers and Drug Therapy
Role: lead
Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation
Role: lead
KONVERT-AF - Relevance of Point in Time for Conversion of Acute Atrial Fibrillation
Role: lead
All 17 trials loaded